Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts

LOS ANGELES, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Investors in Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) have until October 20, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Fractyl Health, Inc. case, Lorne v. Fractyl Health, Inc., et al., was filed on August 21, 2026 and is pending in the U.S. District Court for the Southern District of New York (Case No. 1:26-cv-07167).

Investors who suffered losses on Fractyl Health, Inc. investments can contact Glancy about the Fractyl Health, Inc. class action to learn about potentially pursuing claims under the federal securities laws before the October 20, 2026 deadline.

Deadline and key dates for Fractyl Health, Inc. investors

Lead plaintiff deadline: October 20, 2026
Class period: January 13, 2025 to January 29, 2026, inclusive
Complaint filed: August 21, 2026
Court: U.S. District Court for the Southern District of New York

What happened?

On January 29, 2026, before the market opened, Fractyl issued a press release announcing six-month data from the REMAIN-1 Midpoint Cohort. During a conference call held the same morning, Chief Executive Officer Harith Rajagopalan indicated that problems at one study site, which had experienced higher-than-expected weight regain across both arms, were at least partly responsible for the cohort's disappointing six-month efficacy results.

On this news, Fractyl's stock price fell $1.25 per share, or 68.04%, to close at $0.58 per share on January 29, 2026, thereby injuring investors.

What does the Fractyl Health, Inc. complaint allege?

The Fractyl Health, Inc. securities lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Fractyl Health, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; (2) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy; and (3) as a result, defendants' positive statements about Fractyl Health, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Investors who purchased or otherwise acquired Fractyl Health, Inc. securities during the class period may move the Court no later than October 20, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

"The complaint filed against Fractyl Health, Inc. alleges that, among other things, the Company failed to disclose that Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results. Investors who want to help lead this case must ask the Court by October 20, 2026, and that date is coming soon," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm that can help Fractyl Health, Inc. investors evaluate potential claims to recover their losses. Investors who wish to serve as lead plaintiff in the Fractyl Health, Inc. class action must move the Court by October 20, 2026. To learn more, visit the Fractyl Health, Inc. case page, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the Fractyl Health, Inc. class, you need not take any action at this time. You may retain counsel of your choice or take no action and remain an absent class member. No class has been certified yet in the Fractyl Health, Inc. case.

Frequently Asked Questions

Who is eligible? Investors who purchased or otherwise acquired Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026 and suffered losses may be members of the proposed class in the Fractyl Health, Inc. shareholder lawsuit.

When is the Fractyl Health, Inc. lead plaintiff deadline? Motions to serve as lead plaintiff in the Fractyl Health, Inc. class action must be filed with the U.S. District Court for the Southern District of New York by October 20, 2026.

What if I miss the Fractyl Health, Inc. deadline? After October 20, 2026, investors generally can no longer ask to be appointed lead plaintiff, but Fractyl Health, Inc. investors may still remain class members. Their ability to share in any future recovery does not depend on serving as lead plaintiff.

What is a lead plaintiff? In the Fractyl Health, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.

Does it cost anything to contact Glancy or participate in this action? Glancy represents Fractyl Health, Inc. investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.

Why work with Glancy on the Fractyl Health, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Fractyl Health, Inc. class action. Prior results do not guarantee a similar outcome.

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

Contact

Charles H. Linehan

Glancy Prongay Wolke & Rotter LLP

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

Email: shareholders@glancylaw.com

Telephone: 310-201-9150 | Toll-free: 888-773-9224

www.glancylaw.com

Follow Glancy on LinkedIn, X, or Facebook.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.